Regeneron Pharmaceuticals Inc. (REGN) Stock

Regeneron Pharmaceuticals Inc. trades at a P/E ratio of 13.24, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 14.24 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 1.08 indicates reasonable value when growth is considered.

With a beta of 0.31, Regeneron Pharmaceuticals Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.91 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Regeneron Pharmaceuticals Inc. achieves a profit margin of 31.90%, meaning it retains $31.90 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 19.90% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 16.00% and ROA at 6.91%, the company generates strong returns on invested capital.

Regeneron Pharmaceuticals Inc.'s revenue declined by 3.70% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings increased by 15.90% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Regeneron Pharmaceuticals Inc. offers a dividend yield of 0.68%, paying $0.88 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of 5/20/2025.

The dividend sustainability can be assessed through the payout ratio - Regeneron Pharmaceuticals Inc. pays $0.88 per share in dividends against earnings of $39.34 per share, resulting in a payout ratio of 2.24%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for 6/6/2025.

Regeneron Pharmaceuticals Inc. has a market capitalization of $56.25B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 106.15M shares outstanding, the company's ownership is relatively concentrated. As a participant in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

Regeneron Pharmaceuticals Inc.'s book value per share is $277.50, while the current stock price is $563.53, resulting in a price-to-book (P/B) ratio of 2.03. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

25 analysts cover REGN with 76% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $727.21 implies 29.0% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:6 Strong Buy, 13 Buy, 5 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.